Key result
Novel biomarkers including thrombospondin-1/CD47 and IL-1β offer mechanistic insights to guide future cardiorenal syndrome therapies.
Why the study?
Current subtypes of cardiorenal syndrome lack precision, and traditional biomarkers such as serum creatinine are limited in providing early and accurate diagnosis.
Novel biomarkers reflecting specific pathophysiological pathways offer potential for improved diagnosis, prognostication, and targeted therapeutic development in cardiorenal syndrome.
No takes yet. Share an insight, caveat, or question.
Should not yet change cardiorenal practice; leaves open targeted trials of thrombospondin-1/CD47 and IL-1β pathways.
Chung et al. (2022) conducted a review in Cardiorenal syndrome. Novel biomarkers, including the thrombospondin-1/CD47 axis, glycocalyx, and interleukin-1β, offer potential insights into the mechanistic basis of cardiorenal syndrome and may guide future targeted therapeutics.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: